Aldeyra Therapeutics Highlights Recent Preclinical Data in Obesity, Atopic Dermatitis, Pain, and Alcoholic Hepatitis, and Announces Planned Pivotal Clinical Trial in Retinitis Pigmentosa, at 2024 Research & Development Day
Aldeyra Therapeutics重点介绍了肥胖、特应性皮炎、疼痛和酒精性肝炎的最新临床前数据,并宣布计划在2024年研发日进行色素性视网膜炎的关键临床试验